Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/2/19 → 10/20/22 |
Funding
- Merck Sharp & Dohme Corporation: $99,855.00
A Phase 3, Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants with Treatment-naive, Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors
- Hao, Zhonglin (PI)